國立高雄大學圖資館 |

語系: 繁體中文

說明(常見問題)

圖資館首頁

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

以平衡計分卡與系統動態學觀點探討台灣製藥產業發展之績效 = Using ...

國立高雄大學亞太工商管理學系碩士班

以平衡計分卡與系統動態學觀點探討台灣製藥產業發展之績效 = Using Balanced Scorecard and System Dynamics in Exploring the Performance of Taiwan's Pharmaceutical Industry

紀錄類型:	書目-語言資料,印刷品 : 單行本
並列題名:	Using Balanced Scorecard and System Dynamics in Exploring the Performance of Taiwan's Pharmaceutical Industry
作者:	楊淑涓,
其他團體作者:	國立高雄大學
出版地:	[高雄市]
出版者:	撰者;
出版年:	民100
面頁冊數:	167面圖，表格 : 30公分;
標題:	平衡計分卡
標題:	Balanced Scorecard (BSC)
電子資源:	http://handle.ncl.edu.tw/11296/ndltd/38044395471145632441
附註:	參考書目：面143-149
附註:	內容為英文
其他題名:	以平衡計分卡與系統動態學觀點探討臺灣製藥產業發展之績效
摘要註:	自1982年以來，台灣已制定許多發展製藥產業的相關策略，但此產業對於台灣之貢獻仍然有限。平衡計分卡(BSC)可以協助轉換策略，形成一套績效指標並管理執行策略之情況，是近年來備受重視且常用於企業層級上的績效衡量方法，然而至目前為止，少有研究將其運用於產業層級上。本研究嘗試結合平衡計分卡與系統動態學來探討台灣製藥產業。主要的研究目的在於以平衡計分卡中的四構面，訂定相關指標以建構台灣製藥產業的複雜系統，並透過系統動態學模擬結果給與政策修正之建議，進而協助提升此產業績效。根據模擬與分析，本研究得出以下之結果：(1)藥價調降比率會導致國內藥品市場銷售成長明顯趨緩；(2)台灣製藥產業的研發經費之來源，以企業與創投為最重要之來源； (3)企業經費就長期而言，投入研發所帶來之營業績效會比投入行銷上之績效好； (4)學習與成長構面的六個衡量變數中，以研發經費為提升研發能力與新藥開發績效最重要之因素，而教育訓練則最有助於提升此產業之營業額。本研究不僅整合平衡計分卡與系統動態學兩種研究工具以給予改善此產業績效之建議，更希望藉此研究結果，協助台灣發展成為亞太地區研發、製造、營運中心。 “Balanced Scorecard (BSC)” is one of the most popular ways of measuring performance and is usually used on the enterprise level; only few studies have ever tried to use it on the industry level. This study tries to combine BSC with SD in order to explore Taiwan’s pharmaceutical industry that had set up the relevant strategies of its development since 1982, but its contribution is still limited at present. Based on the four dimensions of BSC, the related indicators will be conducted in this study. The main purpose of this study is to investigate and build the complex system of Taiwan’s pharmaceutical industry; then, amend the policy direction to enhance its performance. According to the outcomes of the simulation and analysis, some findings have been revealed as follows: (1) the policy of drug-cutting prices rate will result in the obvious slow-down of the domestic pharmaceutical market; (2) the most important fund sources of R&D mainly comes from the enterprise and venture capital; (3) in the long term, reducing 10% marketing funding and using this 10% to invest in R&D area will bring better performances in new drug development and sales value; (4) R&D funding is the best effective driving force for the increasing “R&D Capability” and “New Drugs Appear in the Market”; while training is the most important factor in the dimension of learning and growth for improving “Sales Value”. This paper not only integrates the research tools and gives the suggestions to improve the performance of this industry, but also assists Taiwan in becoming a center of R&D, manufacturing and operating in Asia-Pacific region in the future.

以平衡計分卡與系統動態學觀點探討台灣製藥產業發展之績效 = Using Balanced Scorecard and System Dynamics in Exploring the Performance of Taiwan's Pharmaceutical Industry
楊, 淑涓

以平衡計分卡與系統動態學觀點探討台灣製藥產業發展之績效 = Using Balanced Scorecard and System Dynamics in Exploring the Performance of Taiwan's Pharmaceutical Industry / 楊淑涓撰 - [高雄市] : 撰者, 民100. - 167面 ; 圖，表格 ; 30公分.
參考書目：面143-149內容為英文.
平衡計分卡Balanced Scorecard (BSC)

以平衡計分卡與系統動態學觀點探討台灣製藥產業發展之績效 = Using Balanced Scorecard and System Dynamics in Exploring the Performance of Taiwan's Pharmaceutical Industry
LDR:04448nam0a2200289 450 001 300310
005 20170214090856.0
009 300310
010 0 $b 精裝
100 $a 20170214y2011 m y0chiy50 e
101 1 $a eng $d chi $d eng
102 $a tw
105 $a ak am 000yy
200 1 $a 以平衡計分卡與系統動態學觀點探討台灣製藥產業發展之績效 $d Using Balanced Scorecard and System Dynamics in Exploring the Performance of Taiwan's Pharmaceutical Industry $z eng $f 楊淑涓撰
210 $a [高雄市] $c 撰者 $d 民100
215 0 $a 167面 $c 圖，表格 $d 30公分
300 $a 參考書目：面143-149
300 $a 內容為英文
314 $a 指導教授：李亭林博士
328 $a 碩士論文--國立高雄大學亞太工商管理學系碩士班
330 $a 自1982年以來，台灣已制定許多發展製藥產業的相關策略，但此產業對於台灣之貢獻仍然有限。平衡計分卡(BSC)可以協助轉換策略，形成一套績效指標並管理執行策略之情況，是近年來備受重視且常用於企業層級上的績效衡量方法，然而至目前為止，少有研究將其運用於產業層級上。本研究嘗試結合平衡計分卡與系統動態學來探討台灣製藥產業。主要的研究目的在於以平衡計分卡中的四構面，訂定相關指標以建構台灣製藥產業的複雜系統，並透過系統動態學模擬結果給與政策修正之建議，進而協助提升此產業績效。根據模擬與分析，本研究得出以下之結果：(1)藥價調降比率會導致國內藥品市場銷售成長明顯趨緩；(2)台灣製藥產業的研發經費之來源，以企業與創投為最重要之來源； (3)企業經費就長期而言，投入研發所帶來之營業績效會比投入行銷上之績效好； (4)學習與成長構面的六個衡量變數中，以研發經費為提升研發能力與新藥開發績效最重要之因素，而教育訓練則最有助於提升此產業之營業額。本研究不僅整合平衡計分卡與系統動態學兩種研究工具以給予改善此產業績效之建議，更希望藉此研究結果，協助台灣發展成為亞太地區研發、製造、營運中心。 “Balanced Scorecard (BSC)” is one of the most popular ways of measuring performance and is usually used on the enterprise level; only few studies have ever tried to use it on the industry level. This study tries to combine BSC with SD in order to explore Taiwan’s pharmaceutical industry that had set up the relevant strategies of its development since 1982, but its contribution is still limited at present. Based on the four dimensions of BSC, the related indicators will be conducted in this study. The main purpose of this study is to investigate and build the complex system of Taiwan’s pharmaceutical industry; then, amend the policy direction to enhance its performance. According to the outcomes of the simulation and analysis, some findings have been revealed as follows: (1) the policy of drug-cutting prices rate will result in the obvious slow-down of the domestic pharmaceutical market; (2) the most important fund sources of R&D mainly comes from the enterprise and venture capital; (3) in the long term, reducing 10% marketing funding and using this 10% to invest in R&D area will bring better performances in new drug development and sales value; (4) R&D funding is the best effective driving force for the increasing “R&D Capability” and “New Drugs Appear in the Market”; while training is the most important factor in the dimension of learning and growth for improving “Sales Value”. This paper not only integrates the research tools and gives the suggestions to improve the performance of this industry, but also assists Taiwan in becoming a center of R&D, manufacturing and operating in Asia-Pacific region in the future.
510 1 $a Using Balanced Scorecard and System Dynamics in Exploring the Performance of Taiwan's Pharmaceutical Industry $z eng
517 1 $a 以平衡計分卡與系統動態學觀點探討臺灣製藥產業發展之績效 $z chi
610 0 $a 平衡計分卡 $a 系統動態(力)學 $a 製藥產業 $a 績效
610 1 $a Balanced Scorecard (BSC) $a System Dynamics (SD) $a Pharmaceutical Industry $a Performance
681 $a 008M/0019 $b 343425 4633 $v 2007年版
700 1 $a 楊 $b 淑涓 $4 撰 $3 518719
712 0 2 $a 國立高雄大學 $b 亞太工商管理學系碩士班 $3 166023
801 0 $a tw $b NUK $c 20111020 $g CCR
856 7 $z 電子資源 $2 http $u http://handle.ncl.edu.tw/11296/ndltd/38044395471145632441